Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- West Pharmaceutical Services, Inc.
- Eli Lilly
Performance comparée (base 100)
Chaque actif vaut 100 au 13 octobre 2025 ; une valeur de 120 signifie +20 % depuis cette date (dernière date commune : 9 octobre 2026).
Indicateurs
« Sans objet » signale un indicateur qui n'a pas de sens pour ce type d'actif : il ne faut pas le comparer.
| Indicateur | West Pharmaceutical Services, Inc.Stock | Eli LillyStock |
|---|---|---|
| Performance et risque | ||
| Performance over the periodChange in price between the first and last common dates. | +39.4% | +43.9% |
| Annualized performanceAverage annual return that would produce the same total performance. | +40.0% | +44.5% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 33.6% | 34.6% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −24.8% | −23.3% |
| Sharpe RatioReturn achieved above the risk-free rate (5.24%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | 1.27 | 1.39 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −3.0% | −2.7% |
| Fondamentaux | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 25.76B $ | 1.05T $ |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 46.9 | 39.6 |
| Price-to-SalesMarket capitalization divided by annual revenue. | 7.7 | 13.2 |
| Net marginShare of revenue retained as profit. | 17.0% | 33.5% |
| Return on equityReturn on equity (ROE). | 19.1% | 102.3% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +13.8% | +47.7% |
| Dividend yieldAnnual dividend relative to the share price. | 0.24% | 0.59% |
| Debt / equityFinancial debt relative to shareholders' equity. | 11% | 162% |
Corrélations sur la période
De −1 à 1 : proche de 1, les deux actifs montent et baissent ensemble ; proche de 0, ils évoluent indépendamment.
- West Pharmaceutical Services, Inc. / Eli Lilly0,18
Analyse comparative
Analyse générée par IAL'IA compare les actifs sélectionnés à partir des seuls chiffres ci-dessus, en signalant ce qui n'est pas comparable. Le texte n'est généré qu'à votre demande.
Informations fournies à titre pédagogique. Elles ne constituent ni un conseil en investissement ni une recommandation personnalisée. Les performances passées ne préjugent pas des performances futures.